Here are four things to know:
1. The AttraX Scaffold is an absorbent ceramic-collagen bone graft with surface technology designed to drive mesenchymal stem cell differentiation into osteoblasts without added growth factors.
2. Available in strips, blocks and morsels, the AttraX Scaffold complements NuVasive’s currently marketed AttraX Putty product line to offer spine surgeons a suite of surface-optimized ceramic graft materials.
3. During preclinical testing in posterolateral fusion models, fusion rates with AttraX were equivalent to or better than autograft and faster than traditional ceramic grafts.
4. NuVasive biologics portfolio includes Osteocel in the cellular allograft category; Propel in the demineralized bone matrix category; and AttraX in the synthetic category.
More articles on biologics:
Spine biologics market to grow at CAGR of 4.09% through 2022
3 things to know about Lattice Biologics
8 key surgeon Q&As on biologics in orthopedics & spine
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
